A small-scale bioreactor that you can setup in 10 minutes!
For whitepapers and more info, visit http://www.atSpiro.com or send us a mail on hi@atspiro.com

Stop blaming a “slow metabolism” ❌ and start DOING something about it! ✅

Here’s some amazing news for anyone who feels like they’re on the slow road to getting in shape…

Even though most people believe they’re “stuck” with a slow metabolism, there are plenty of things you can do to speed things up (9 things in particular ????).

Things like:

✔️Changing your diet
✔️Understanding your body’s unique metabolic makeup
✔️And even certain types of exercise

And I know — I can already hear you saying, “But Dom, I’ve tried SO many different diets and exercises and NOTHING works!”

I get it.

And, that’s why I’ve put together a FREE guide, Master Your Metabolism, so you can understand WHY things haven’t worked and what WILL.

Inside, you’ll not only find 9 proven ways to get your engine revving…

You’ll also learn:

???? How our metabolism works and what makes it “hackable”
???? The truth about how much aging affects our metabolic rate
???? The number you need to pay attention to if you want to hit your goals

And a whole lot more :)

Click https://www.domagojdraganic.com/mym to grab the guide for FREE!

 

 

European Innovation Council Accelerator finances treatment development drive for condition
The European Innovation Council (EIC) Accelerator is providing €16m to support the development of therapy to slow the progression of Parkinson's disease.
GeneCode will receive the financing to support the Kevad Bio project, which is being developed in collaboration with Argobio, and is divided into a €1.7m grant and €14.3m in equity investments.
GeneCode is a company focused on the development of disease-modifying therapeutics to combat neurodegeneration, while Argobio is a start-up that concentrates on progressing innovation.
For the critical second 2023 EIC Accelerator ‘cut-off’ in March this year, well over 500 businesses submitted a complete application. Consequently, a set of 51 companies across 17 different countries were selected during a competitive process to receive the vital funding.
The funding provided to GeneCode amounts to €16m – under EIC Accelerator, a single project can receive a maximum of €17.5m.
Professor Mart Saarma, GeneCode supervisory board member, reflected: “If we can contribute to improving the quality of life of people affected by the disease through our treatment, it will be a great achievement. Renowned specialists from GeneCode and Argobio, as well as several researchers from the Universities of Tartu and Helsinki and international CROs, are contributing to this effort daily.”
He added: “We are now in the position to start preparations to achieve the IND-ready status to apply for a licence for clinical trials.”
Read more: https://www.pharmatimes.com/news/genecode_receives_record_parkinsons_funding_1494255

Hi Everyone,
I'm glad to be member of PHARMeMED.I think that being part of this open and ethical community would be an opportunity for me since I am a person who is very interested in keeping up to date with the news.
Thanks!

The collaboration aims to develop novel preclinical models with a view to identifying new treatments
Almirall – a company which concentrates on medical dermatology – has linked up with the Centre for Genomic Regulation. The collaboration aims to develop novel preclinical models with a view to identifying new treatments for non-melanoma skin cancer (NMSC).
The condition poses a considerable health challenge, with basal cell carcinoma and squamous cell carcinoma representing 70% and 25% of NMSC cases, respectively.
The partnership – led by Almirall's investigators Dr Cristina Gutiérrez and Dr Amadeu Gavaldà – will also incorporate CRG group leader and ICREA research professor Luciano Di Croce and his team.
In partnership, they will establish experimental models that enable the validation of new therapeutic approaches and therapies for these diseases.
The collaboration has emerged following the request for proposals from AlmirallShare – the company's open innovation platform dedicated to discovering treatments for skin diseases.
The platform was launched in 2017 in order to make dermatological study collaborations more straight forward and the development of new skin condition treatments more rapid.
Professor Di Croce was optimistic about the collaboration: “NMSC is not an aggressive cancer, meaning it has been historically difficult to model this disease in the lab. However, important technological advances combined with multiple 'omics’ approaches allow now to create truly functional scientific models for this skin cancer.”
Read more: https://www.pharmatimes.com/news/centre_for_genomic_regulation_and_almirall_join_forces_on_skin_cancer_treatments_1492027

http://www.4catalyzer.com, founded by Dr. Jonathan Rothberg, is hiring a Software Engineer for our newest genomics start-up company, 454 Bio. https://454.bio/
This is an exciting GROUND FLOOR opportunity!
454 Bio was founded by a group of leading genomics experts who are developing a DNA sequencing platform for use at home, for under $100 – it’s an innovative product and an exciting time to join the team!
You would play a critical role & work with the company’s founders to develop next-gen molecular biology systems to interface with novel engineering platforms.
We're looking for someone with experience in:
● Life science tools
● Data processing for NGS (highly preferred)
● Deep knowledge and experience of:
○ Image processing: automatic ROI detection and analysis
○ Developing software for automated test equipment
○ Custom design and code analysis scripts
○ Python, with some knowledge of C++ preferred
○ Designing efficient algorithms that can run on low-end hardware
● Ability to analyze own data (fluency with R, or MATLAB preferred)
Here is the role: https://www.4catalyzer.com/careers?gh_jid=5568169003
Please apply, or get in touch for more information - happy to provide full details.
The lab is based in Guilford, CT.
Visa sponsorship can be considered.

Passed ISO9001 quality certification system!

http://www.4catalyzer.com, founded by Jonathan Rothberg, is hiring TWO Molecular Biologists for their newest genomics start-up company, 454 Bio. https://454.bio/
This is an exciting GROUND FLOOR opportunity!
454 Bio was founded by a group of leading genomics experts who are developing a DNA sequencing platform for use at home, for under $100 – it’s an innovative product and an exciting time to join the team!
You would play a critical role & work with the company’s founders to develop next-gen molecular biology systems to interface with novel engineering platforms.
We're looking for someone with experience in:
- Surface amplification and library prep using fragmentation
- application of sequencing techniques
- researching and designing assays
- DNA patterned array design, development, and production
- NGS
Here is the role: https://www.4catalyzer.com/careers?gh_jid=5326749003
Please get in touch for more information - happy to provide full details.
The lab is based in Guilford, CT.
Visa sponsorship can be considered.

Question - Does anyone use topical anesthesia (creams) for procedures? If so, what formulation do you use?

Question - Does anyone use topical anesthesia (creams) for procedures? If so, what formulation do you use?

Hi everyone, I'm happy to join you here. hope to find interesting topics to talk about and share interesting information.

Please right profile show me. 

Novo Nordisk said on Tuesday it would cut U.S. list prices for several insulin drugs by up to 75% next year, joining rival Eli Lilly as drugmakers come under pressure for high prices of the life-sustaining treatment.
The moves follow President Joe Biden's Inflation Reduction Act last year that capped insulin prices for Medicare recipients at $35 per month, but that does not extend to patients without insurance.
Novo will reduce the list price of its NovoLog insulin by 75%, and for Novolin and Levemir by 65%. The Danish drugmaker said the financial impact of the move was uncertain.
The company also said it would reduce the list price of unbranded insulin products to match lowered price of respective branded insulin products.
Eli Lilly and Co said earlier this month that it would cut the list prices for its most commonly prescribed insulin products by 70% from the fourth quarter of this year.
"I think it is a relatively natural consequence of what we have seen their competitor Eli Lilly do. We know there has been political pressure on this issue in general, it is a focus area in the U.S., especially for uninsured patients," Jyske Markets analyst Henrik Hallengreen Laustsen told Reuters.
Read more: https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-cut-price-insulin-by-up-75-wsj-2023-03-14/

Candidate AP30663 is an inhibitor for the conversion of atrial fibrillation to a normal sinus rhythm
Acesion Pharma – a company focused on novel therapies for atrial fibrillation (AF) – has announced positive results from a phase 2 trial of its candidate, AP30663. The therapy is a first-in-class SK ion channel inhibitor for the conversion of AF to a normal sinus rhythm.
The trial was placebo-controlled, randomised, double-blind and multi-national. The study enrolled 63 patients with a current episode of AF – the most common cardiac arrhythmia – and examined the performance of two intravenous doses of AP30663 compared to the placebo.
Meanwhile, the primary endpoint was the proportion of patients with AF conversion to sinus rhythm within 90 minutes of infusion commencing.
In addition, the research employed a ‘Bayesian analysis’ involving a probability less than 99.9% of a true AF conversion rate greater than the placebo across the two doses. The results from the Bayesian analysis were supported by a traditional analysis of the primary endpoint, demonstrating significant P-values for each dose compared to the placebo.
The safety profile was also consistent with that observed in previous phase 1 trials with AP30663, while the therapy was well tolerated, with no serious adverse events reported among the groups. The main safety concern with available AF treatments – ventricular arrhythmias – were not apparent throughout the trials.
John Camm, emeritus professor of clinical cardiology at St George’s University of London, reflected: “There is a great unmet need for safer AF treatments that can decrease the risk for patients, but also remove barriers for physicians wanting to keep their patients in sinus rhythm by treating them with an antiarrhythmic drug. This novel mechanism holds the promise to deliver on these aspects.”
Read more: https://www.pharmatimes.com/news/acesion_announces_positive_atrial_fibrillation_study_1489340

Consider following MEDAMETHEUS on LinkedIn, especially if you need a versatile medical affairs partner!